Oral Bioavailability and Disposition of [14C]Omapatrilat in Healthy Subjects-Reference-Cited by-同舟云学术

Oral Bioavailability and Disposition of [14C]Omapatrilat in Healthy Subjects

Published:2001-08 Issue:8 Volume:41 Page:833-841
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:

Author:

Malhotra Bimal K.,Iyer Ramaswamy A.,Soucek Kathy M.,Behr Douglas,Liao Wei-chi,Mitroka James G.,Kaul Sanjeev,Cohen Marvin B.,Knupp Catherine A.

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference34 articles.

1. Recent advances in the design and development of vasopeptidase inhibitors;Robl;Exp Opin Ther Patents,1999

2. Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril;Trippodo;J Cardiovasc Pharmacol,1999

3. Cardiovascular effects of the novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme BMS-182657 in experimental hypertension and heart failure;Trippodo;J Pharmacol Exp Ther,1995

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Possible contribution of the neprilysin/ACE pathway to sepsis in mice;Life Sciences;2020-10

2. Clinical Pharmacokinetics of Drugs in Patients with Heart Failure: An Update (Part 2, Drugs Administered Orally);Clinical Pharmacokinetics;2014-09-24

3. Clinical Pharmacokinetics of Drugs in Patients with Heart Failure;Clinical Pharmacokinetics;2013-01-24

4. Omapatrilat;xPharm: The Comprehensive Pharmacology Reference;2008

5. METABOLISM OF [14C]GEMOPATRILAT AFTER ORAL ADMINISTRATION TO RATS, DOGS, AND HUMANS;Drug Metabolism and Disposition;2006-03-15